LivaNova (LIVN) Projected to Post Earnings on Wednesday

LivaNova (NASDAQ:LIVN) is projected to post its Q2 2026 results before the market opens on Wednesday, August 5th. Analysts expect the company to announce earnings of $1.09 per share and revenue of $380.5370 million for the quarter. LivaNova has set its FY 2026 guidance at 4.200-4.300 EPS. Parties can find conference call details on the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 8:00 AM ET.

LivaNova (NASDAQ:LIVN) last issued its earnings results on Wednesday, May 6th. The company reported $0.98 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.85 by $0.13. LivaNova had a net margin of 7.48% and a return on equity of 16.48%. The firm had revenue of $362.26 million for the quarter, compared to the consensus estimate of $346.05 million. During the same quarter in the prior year, the firm posted $0.88 earnings per share. The business’s revenue was up 14.3% on a year-over-year basis. On average, analysts expect LivaNova to post $4 EPS for the current fiscal year and $4 EPS for the next fiscal year.

LivaNova Trading Up 2.9%

NASDAQ:LIVN opened at $82.46 on Tuesday. The stock has a market cap of $4.53 billion, a price-to-earnings ratio of 42.29 and a beta of 0.86. The company has a quick ratio of 1.11, a current ratio of 1.33 and a debt-to-equity ratio of 0.24. The company’s 50 day moving average price is $79.26 and its 200-day moving average price is $70.33. LivaNova has a 52 week low of $41.13 and a 52 week high of $85.27.

Insider Transactions at LivaNova

In other LivaNova news, Director Francesco Bianchi sold 1,800 shares of LivaNova stock in a transaction that occurred on Tuesday, May 26th. The shares were sold at an average price of $75.75, for a total value of $136,350.00. Following the completion of the sale, the director owned 7,228 shares of the company’s stock, valued at approximately $547,521. The trade was a 19.94% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.35% of the company’s stock.

Hedge Funds Weigh In On LivaNova

Several hedge funds and other institutional investors have recently modified their holdings of the company. Empowered Funds LLC bought a new stake in shares of LivaNova during the 4th quarter valued at about $107,000. Northwestern Mutual Wealth Management Co. bought a new position in shares of LivaNova in the 4th quarter worth approximately $145,000. iSAM Funds UK Ltd bought a new position in shares of LivaNova in the 3rd quarter worth approximately $218,000. Headlands Technologies LLC boosted its holdings in shares of LivaNova by 270.8% in the second quarter. Headlands Technologies LLC now owns 3,456 shares of the company’s stock worth $156,000 after buying an additional 2,524 shares during the last quarter. Finally, Captrust Financial Advisors purchased a new position in shares of LivaNova in the second quarter worth approximately $218,000. 97.64% of the stock is owned by institutional investors.

Analyst Ratings Changes

LIVN has been the topic of several analyst reports. Zacks Research raised LivaNova from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, July 21st. Mizuho lifted their target price on LivaNova from $90.00 to $95.00 and gave the stock an “outperform” rating in a report on Wednesday, July 15th. Freedom Capital upgraded LivaNova to a “hold” rating in a research note on Tuesday, June 30th. Weiss Ratings raised LivaNova from a “sell (d+)” rating to a “hold (c)” rating in a report on Thursday, May 7th. Finally, Barclays upped their price target on LivaNova from $73.00 to $76.00 and gave the company an “equal weight” rating in a report on Thursday, May 7th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $81.38.

About LivaNova

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.